A61K 39/0283
Shigella
Official title: {Shigella}
A61K39/0283 (Shigella) appears on 121 US grants and 152 published applications in this corpus.
Search patents in A61K- Granted patents
- 121
- Published applications
- 152
- Assignees
- 106
- Inventors
- 238
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 3 | 1 |
| 2002 | 2 | 6 |
| 2003 | 0 | 1 |
| 2004 | 4 | 5 |
| 2005 | 6 | 6 |
| 2006 | 7 | 5 |
| 2007 | 3 | 5 |
| 2008 | 1 | 7 |
| 2009 | 2 | 2 |
| 2010 | 4 | 9 |
| 2011 | 3 | 6 |
| 2012 | 8 | 4 |
| 2013 | 0 | 8 |
| 2014 | 8 | 9 |
| 2015 | 9 | 13 |
| 2016 | 6 | 4 |
| 2017 | 7 | 7 |
| 2018 | 3 | 5 |
| 2019 | 4 | 6 |
| 2020 | 5 | 5 |
| 2021 | 5 | 6 |
| 2022 | 5 | 7 |
| 2023 | 3 | 7 |
| 2024 | 5 | 11 |
| 2025 | 4 | 2 |
| 2026 | 3 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- High dose shigella vaccine preparation26 May 2026US 12,636,356 B2Eveliqure Biotechnologies GmbH
- Method for the production of outer membrane vesicles and immunogenic compositions thereof17 Feb 2026US 12,551,544 B2Biomvis Srl
- Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof20 Jan 2026US 12,527,854 B2Aphp (Assistance Publique - HôPitaux De Paris)
- Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production23 Sep 2025US 12,419,947 B2Najit Technologies, Inc.
- Live attenuated oral vaccine against shigellosis and typhoid fever9 Sep 2025US 12,409,213 B2Sanaria Inc.
- A broadly protective prophylactic vaccine against pseudomonas aeruginosa24 Sep 2026US 2026/0284172 A1University of Kansas
- Modified carrier proteins for o-linked glycosylation6 Aug 2026US 2026/0224696 A1Glaxosmithkline Biologicals SA
- Shigella multiple antigen presenting immunogenic composition and fusion proteins thereof28 May 2026US 2026/0144857 A1Children's Medical Center Corporation
- Methods of producing shiga toxin b-subunit (stxb) monomers and oligomers, and uses thereof21 May 2026US 2026/0137765 A1Aphp (Assistance Publique - HôPitaux De Paris)
- Intranasal polysaccharide conjugate nanomulsion vaccines and methods of using the same8 Jan 2026US 2026/0007731 A1BlueWillow Biologics, Inc.
Most cited
By later US patents
- Shigella vector for delivering DNA to a mammalian cell99US 5,824,538 AThe United States of America as represented by the Secretary of the Army · 1998
- Novel non-reverting shigella live vaccines87US 5,077,044 AThe Board of Trustees of the Leland Stanford Jr. University · 1991
- Non-reventing live vaccines54US 5,210,035 AThe Board of Trustees of the Leland Stanford Jr. University · 1993
- Invaplex from gram negative bacteria, method of purification and methods of use48US 6,245,892 B1The United States of America as represented by the Secretary of the Army · 2001
- Prevention and treatment of rheumatoid arthritis36US 4,732,757 AStolle Research & Development Corporation · 1988